# ErVimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ervimmune

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.ervimmune.com/
- Total disclosed funding: $21M
- Latest round: Series A (Jan 6, 2026)
- Investors on record: 2

## About

Based in Lyon, France, ErVimmune specializes in developing innovative cancer immunotherapies, focusing on vaccines and T cell-based therapies that target cold tumors through advanced AI-driven technology.Founded in 2019 and headquartered in Lyon, France, ErVimmune develops immunotherapy solutions for cancer treatment. The company has secured EUR 17.000 mn in SERIES A funding from investors including SPRIM Global Investments and Seventure Partners on January 6th, 2026, marking its first major funding achievement.ErVimmune specializes in the development of innovative immunotherapies, focusing on cancer vaccines and T cell-based therapies that specifically target cold tumors. Utilizing a proprietary, AI-driven target discovery platform, the company identifies non-conventional antigens derived from human endogenous retroviruses (HERVs). This unique approach enables ErVimmune to create therapies aimed at addressing critical unmet medical needs in cancer treatment, particularly by utilizing accurate non-mutated tumor epitopes shared across various patients and cancer types. Their primary clientele includes oncology specialists and medical institutions throughout Europe and North America.ErVimmune's revenue model is largely sustained through strategic partnerships and collaborations with research institutions and healthcare providers, aimed at advancing clinical development programs for their cancer therapies. These collaborations often lead to licensing agreements and research partnerships, facilitating the integration of their technologies into broader clinical frameworks. The pricing of flagship products, including their lead cancer vaccine candidate, will be based on therapeutic value and the outcomes from associated research. The firm's revenue will be impacted by the successful progression of clinical trials and the subsequent approval of products in key markets.Looking ahead, ErVimmune plans to utilize the EUR 17.000 mn raised in SERIES A funding to secure additional non-dilutive support from Bpifrance and France’s 2030 investment program. The funds will aid in the enhancement of their cancer therapies and the expansion of their market presence. The company aims to introduce new products targeting specific cancer indications and is also focusing on geographical expansion within Europe and North America by 2026.

## Funding rounds

- Series A, Jan 6, 2026, $20M — Seventure Partners, Sprim Ventures
- Seed, Feb 5, 2021, $1.4M — Seventure Partners

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Seed, Series A
- Sprim Ventures (https://capitalatlas.ai/funds/sprim-ventures) — Series A